Stents, by Ryan Colombo: Difference between revisions
| Line 5: | Line 5: | ||
One of the major problems with bare metal stents is the occurrence of neointimal hyperplasia following impantation [1]. This leads to restentosis, or a re-narrowing of the blood veseel, and requires revascularization. This has occurred in up to a third of patients treated with bare metal stents [1]. | One of the major problems with bare metal stents is the occurrence of neointimal hyperplasia following impantation [1]. This leads to restentosis, or a re-narrowing of the blood veseel, and requires revascularization. This has occurred in up to a third of patients treated with bare metal stents [1]. | ||
=Drug Eluting Stents= | |||
==First Generation Drug Eluting Stents== | ==First Generation Drug Eluting Stents== | ||
Revision as of 19:24, 26 February 2013
Background
Precutaneous coronary intervention, pioneered by Dr. Gruntzig in 1977, is the most frequently performed medical procedure [1]. In the past, this was performed using balloon angioplasty. However, this procedure was subject to detrimental vessel closure due to dissection and restentosis [1]. The stent was developed to maintain lumen integrity.
Bare Metal Stents
One of the major problems with bare metal stents is the occurrence of neointimal hyperplasia following impantation [1]. This leads to restentosis, or a re-narrowing of the blood veseel, and requires revascularization. This has occurred in up to a third of patients treated with bare metal stents [1].
Drug Eluting Stents
First Generation Drug Eluting Stents
Second Generation Drug Eluting Stents
References
[1] Stefanini G., Holmes D. Drug eluting coronary-artery stents. New England Journal of Medicine, 2013, 368:254-65.
